Sarah C. Gilbert focuses on Immunology, Virology, Immunogenicity, Vaccination and Vaccinia. Her Virology research includes themes of Cytotoxic T cell, Viral vector, Recombinant DNA and Antigen. Her Immunogenicity research incorporates themes from ELISPOT, Viral Vaccine, Adverse effect and Modified vaccinia Ankara.
Her studies deal with areas such as Clinical research, Clinical trial, Regimen, Heterologous and Reactogenicity as well as Vaccination. Her study in Vaccinia is interdisciplinary in nature, drawing from both Interferon and DNA vaccination. Her work carried out in the field of Plasmodium falciparum brings together such families of science as Antibody and Vaccine efficacy.
Sarah C. Gilbert mainly investigates Virology, Immunology, Vaccination, Immunogenicity and Antigen. Her work deals with themes such as Vaccinia, Plasmodium falciparum, Viral vector and Immune system, which intersect with Virology. Her Vaccinia study integrates concerns from other disciplines, such as Immunization and DNA vaccination.
Her study looks at the intersection of Immunology and topics like Cytotoxic T cell with CD8, Priming and Plasmodium berghei. Her studies deal with areas such as Cellular immunity, Heterologous, Regimen and Modified vaccinia Ankara as well as Vaccination. The various areas that Sarah C. Gilbert examines in her Immunogenicity study include ELISPOT, Viral Vaccine, Adenoviridae and Adjuvant.
Her scientific interests lie mostly in Virology, Vaccination, Immunogenicity, Virus and Antibody. Her Virology research is multidisciplinary, incorporating elements of Heterologous, Viral vector, Antigen and Severe acute respiratory syndrome coronavirus 2. Her study with Vaccination involves better knowledge in Immunology.
Sarah C. Gilbert has included themes like T cell, Booster dose, Viral Vaccine and Immunity in her Immunogenicity study. Her Virus study combines topics from a wide range of disciplines, such as Transmission, Vaccinia and Pandemic. Her Antibody research is multidisciplinary, relying on both Receptor, Viral replication and Recombinant DNA.
Vaccination, Immunogenicity, Virology, Antibody and Adverse effect are her primary areas of study. Her work carried out in the field of Vaccination brings together such families of science as Virus, Viral load, Booster dose and Modified vaccinia Ankara. Her Virus research is multidisciplinary, incorporating perspectives in Vaccinia and Heterologous.
Sarah C. Gilbert is doing genetic studies as part of her Immunology and Immune system and Immunogenicity investigations. Sarah C. Gilbert has researched Virology in several fields, including Epitope and Severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019. She interconnects Receptor and Coronavirus in the investigation of issues within Antibody.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
P M Folegatti;K J Ewer;P K Aley;B Angus.
The Lancet (2020)
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
Jörg Schneider;Sarah C. Gilbert;Tom J. Blanchard;Tomas Hanke.
Nature Medicine (1998)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
M Voysey;Clemens Sac.;S A Madhi;L Y Weckx.
The Lancet (2021)
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
Helen McShane;Ansar A Pathan;Clare R Sander;Sheila M Keating.
Nature Medicine (2004)
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
Samuel J McConkey;William H H Reece;Vasee S Moorthy;Daniel Webster.
Nature Medicine (2003)
Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria.
C Ruwende;S C Khoo;R W Snow;S N Yates.
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.
Neeltje van Doremalen;Teresa Lambe;Alexandra Spencer;Sandra Belij-Rammerstorfer.
Upregulation of TGF-β, FOXP3, and CD4+CD25+ Regulatory T Cells Correlates with More Rapid Parasite Growth in Human Malaria Infection
Michael Walther;Jon Eric Tongren;Laura Andrews;Daniel Korbel.
Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1
Tamara K. Berthoud;Matthew Hamill;Patrick J. Lillie;Lenias Hwenda.
Clinical Infectious Diseases (2011)
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
Daniel P. Webster;Susanna Dunachie;Jenni M. Vuola;Tamara Berthoud.
Proceedings of the National Academy of Sciences of the United States of America (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: